Candel Therapeutics, Inc. (CADL)
CADLNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$6.23
-2.16 (-25.74%) today
Regular session, Nov 13, 11:28 AM ET
- Market cap
- $488.72m
- P/E
- –
- EPS, last 4 quarters
- $-1.31
- Dividend yield
- –
- Day range
- $5.20 to $6.26
- 52-week range
- $4.35 to $14.00
- Average volume
- –
- Previous close
- $8.39
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $18.50, +197.0% from here
Earnings
next estimate $-0.3300Next report
Dec 2025
-125.0%
Mar 2026
+36.4%
Jun 2026
-59.1%
Sep 2026
+6.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$13.21m | -$15.75m | -$16.28m | -$26.75m |
| Net income | -$11.27m | -$29.50m | -$8.86m | -$38.91m |
News
8 latest- Candel Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Plans Middle of 2027 BLA Submission for AglatimageneFintel · 3 hours ago
- Candel Therapeutics Outlines Mid-2027 BLA Plan For Aglatimagene Following Q3 Results RTTNews · 4 hours ago
- Candel's Aglatimagene Shows Prolonged Survival In Phase 2a NSCLC Trial RTTNews · Oct 1, 2026
- Candel Reports 24.5-Month Survival In Phase 2a NSCLC Study RTTNews · Oct 1, 2026
- Stocks Settle Sharply Higher as Crude Prices Plunge and Chipmakers SoarBarchart · Sep 22, 2026
- Stocks Supported by Lower Crude Prices and Bond YieldsBarchart · Sep 21, 2026
- Stocks and Bonds Climb as Slumping Crude Prices Ease Inflation RisksBarchart · Sep 21, 2026
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux Zacks · Sep 16, 2026
The company
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- candeltx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.